Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376117 | 0.90 | PTGS1 (0.42) | HTR6PARP1F12MAPKAPK2CYP3A4 | |
| SCHEMBL5376849 | 0.84 | MCHR1 (0.47) | HTR6MCHR1MAPKAPK2HDAC1HDAC6 | |
| SCHEMBL5376877 | 0.84 | MCHR1 (0.50) | HTR6MCHR1HDAC1HDAC6 | |
| SCHEMBL5373439 | 0.81 | HTR6 (0.58) | HTR6HDAC1HDAC6PTGS1PTGS2 | |
| SCHEMBL16610030 | 0.78 | MCHR1 (0.51) | MCHR1CYP3A4 | |
| SCHEMBL5372839 | 0.77 | PTGS1 (0.42) | HTR6MCHR1MAPKAPK2HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL17940522 | 0.77 | KDM4E (0.51) | MCHR1CYP3A4 | |
| SCHEMBL5376070 | 0.76 | HTR2A (0.44) | HTR6MCHR1MAPKAPK2HDAC1HDAC6 | |
| SCHEMBL5367869 | 0.76 | MCHR1 (0.45) | HTR6MCHR1PTGS1PTGS2 | |
| SCHEMBL25685286 | 0.75 | PARP1 (0.42) | HTR6PARP1MCHR1F12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | HTR6 2138/4885PARP1 931/4885MCHR1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.